Kaneria, Nicole Sheena;
Tuleu, Catherine;
Ernest, Terry;
(2022)
Opportunities for enteral drug delivery for neonates, infants and toddlers: a critical exploration.
Expert Opinion on Drug Delivery
, 19
(5)
pp. 475-519.
10.1080/17425247.2022.2064449.
Preview |
Text
Tuleu_Opportunities for enteral drug delivery for neonates infants and toddlers a critical exploration.pdf Download (3MB) | Preview |
Abstract
INTRODUCTION: The field of neonatal, infant and toddler pharmaceutical development is constantly improving, however a lag still remains in comparison to older children and adults. Their rapid anatomical, physiological and behavioural developmental rates pose extra challenges in diagnosing, treating, or preventing their disease. In turn, this brings complexity in formulating truly age-appropriate medicinal products that suit this heterogeneous paediatric subset. Progress in the availability of such products has ensued following the introduction of the 2007 European Union Paediatric Regulation, and in recent years, oral multiparticulate and dispersible solid formulations have gained interest alongside liquid formulations. However, the need is still great for dosage forms that do not compromise on pharmaceutical efficacy, safety and global accessibility in those aged under 2. AREAS COVERED: This article highlights some of the formulation challenges correlated with this age group and critically explores recent solid age-appropriate formulations and their administration devices for enteral drug delivery. EXPERT OPINION: There are many formulation requirements to consider when formulating drug products for children aged under 2. Efforts are required into understanding acceptability in this age group and of their carers, and whether innovation or optimisation is required, to help guide formulators towards optimal approaches without impacting access.
| Type: | Article |
|---|---|
| Title: | Opportunities for enteral drug delivery for neonates, infants and toddlers: a critical exploration |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1080/17425247.2022.2064449 |
| Publisher version: | https://doi.org/10.1080/17425247.2022.2064449 |
| Language: | English |
| Additional information: | Copyright © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | Acceptability, administration device, age-appropriate, dose flexibility, infant, low-middle income countries, nasogastric, neonate, oral/enteral solids, paediatric formulation, rectal drug delivery, toddler |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10147103 |
Archive Staff Only
 |
View Item |
